期刊文献+

The development of neutralizing antibodies against SARS-CoV-2 and their common features

原文传递
导出
摘要 Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has caused a worldwide severe coronavirus disease 2019(COVID-19)pandemic since December 2019.There is a great demand for effective therapies for the prevention and treatment of COVID-19.Developing therapeutic neutralizing antibodies(NAbs),which could block viral infection,is such a promising approach,as NAbs have been successfully applied to the treatment of other viral infections.The recent advances of antibody technology have greatly accelerated the discovery of SARS-CoV-2 NAbs,and many of which are now actively tested in clinical trials.Here,we review the approaches applied for SARS-CoV-2 NAb development,and discuss the emerging technologies underlining the antibody discovery.We further summarize the common features of these antibodies including the shared neutralizing epitopes and sequence features.
出处 《Journal of Molecular Cell Biology》 SCIE CAS CSCD 2020年第12期980-986,共7页 分子细胞生物学报(英文版)
基金 Work in the authors'labs was supported by the National Key R&D Program of China(2017YFA0506700) the National Natural Science Foundation of China(81622022 and 31970880 to F.-L.M.,31722020,81671634,and 8186113801A to L.-S.Y.) Shanghai Jiao Tong University COVID-19 grant to L.-S.Y. Shanghai Science and Technology Committee(20490760200)to F.-L.M.
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部